Key result
Standard-dose DOACs cut stroke or systemic embolism ~19% vs. warfarin in AF.
Why the study?
DOACs are preferred over warfarin in AF, and individual patient data meta-analyses offer substantial advantages over study-level data.
Does standard-dose or lower-dose DOAC reduce stroke or systemic embolism compared to warfarin in patients with atrial fibrillation?
Meta-Analysis (n=71,683)
Yes
Does standard-dose or lower-dose DOAC reduce stroke or systemic embolism compared to warfarin in patients with atrial fibrillation?
Patient-level network meta-analysis confirms DOACs provide superior efficacy and safety compared to warfarin across age groups, with standard-dose DOACs particularly favored in patients without prior VKA use.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We felt we had a public service obligation here. We didn't want the wider community to just be leaving elderly patients on a vitamin K antagonist when we think we have a better alternative. At a minimum, doctors should be having the discussion with elderly patients who are frail and say, 'Look, there is a new class of drugs available. Here are the advantages. Here are the disadvantages. They are more costly. And so let's think about what's best for you.'”
Confirms standard-dose DOACs as preferred over warfarin for stroke prevention in atrial fibrillation; strengthens pooled evidence from four pivotal trials.
Background: Direct oral anticoagulants (DOACs) are preferred over warfarin for stroke prevention in atrial fibrillation. Meta-analyses using individual patient data offer substantial advantages over study-level data. Methods: We used individual patient data from the COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) database, which includes all patients randomized in the 4 pivotal trials of DOACs versus warfarin in atrial fibrillation (RE-LY [Randomized Evaluation of Long-Term Anticoagulation Therapy], ROCKET AF [Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation], ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation], and ENGAGE AF-TIMI 48 [Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48]), to perform network meta-analyses using a stratified Cox model with random effects comparing standard-dose DOAC, lower-dose DOAC, and warfarin. Hazard ratios (HRs [95% CIs]) were calculated for efficacy and safety outcomes. Covariate-by-treatment interaction was estimated for categorical covariates and for age as a continuous covariate, stratified by sex. Results: A total of 71 683 patients were included (29 362 on standard-dose DOAC, 13 049 on lower-dose DOAC, and 29 272 on warfarin). Compared with warfarin, standard-dose DOACs were associated with a significantly lower hazard of stroke or systemic embolism (883/29 312 [3.01%] versus 1080/29 229 [3.69%]; HR, 0.81 [95% CI, 0.74–0.89]), death (2276/29 312 [7.76%] versus 2460/29 229 [8.42%]; HR, 0.92 [95% CI, 0.87–0.97]), and intracranial bleeding (184/29 270 [0.63%] versus 409/29 187 [1.40%]; HR, 0.45 [95% CI, 0.37–0.56]), but no statistically different hazard of major bleeding (1479/29 270 [5.05%] versus 1733/29 187 [5.94%]; HR, 0.86 [95% CI, 0.74–1.01]), whereas lower-dose DOACs were associated with no statistically different hazard of stroke or systemic embolism (531/13 049 [3.96%] versus 1080/29 229 [3.69%]; HR, 1.06 [95% CI, 0.95–1.19]) but a lower hazard of intracranial bleeding (55/12 985 [0.42%] versus 409/29 187 [1.40%]; HR, 0.28 [95% CI, 0.21–0.37]), death (1082/13 049 [8.29%] versus 2460/29 229 [8.42%]; HR, 0.90 [95% CI, 0.83–0.97]), and major bleeding (564/12 985 [4.34%] versus 1733/29 187 [5.94%]; HR, 0.63 [95% CI, 0.45–0.88]). Treatment effects for standard- and lower-dose DOACs versus warfarin were consistent across age and sex for stroke or systemic embolism and death, whereas standard-dose DOACs were favored in patients with no history of vitamin K antagonist use ( P =0.01) and lower creatinine clearance ( P =0.09). For major bleeding, standard-dose DOACs were favored in patients with lower body weight ( P =0.02). In the continuous covariate analysis, younger patients derived greater benefits from standard-dose (interaction P =0.02) and lower-dose DOACs (interaction P =0.01) versus warfarin. Conclusions: Compared with warfarin, DOACs have more favorable efficacy and safety profiles among patients with atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Carnicelli et al. (2022) conducted a meta-analysis in Atrial Fibrillation (n=71,683). Standard-dose DOAC vs. Warfarin was evaluated on Composite of any stroke (ischemic, hemorrhagic, or other) or systemic embolism (HR 0.81, 95% CI 0.74-0.89). Standard-dose DOACs reduced the hazard of stroke or systemic embolism by 19% compared with warfarin in patients with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: